Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease

Aim.То study the levels of asymmetric dimethylarginine (ADMA) and NO metabolites in patients with ST elevation acute coronary syndrome (ACS-ST), as well as in patients with stable effort angina (SEA). Material and methods. The study involved 35 patients: 20 with ACS-ST (mean age 57,4±9,2 years) and...

Full description

Saved in:
Bibliographic Details
Main Authors: A. S. Galyavich, E. R. Gaynutdinov
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2009-02-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/1137
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850028170475995136
author A. S. Galyavich
E. R. Gaynutdinov
author_facet A. S. Galyavich
E. R. Gaynutdinov
author_sort A. S. Galyavich
collection DOAJ
description Aim.То study the levels of asymmetric dimethylarginine (ADMA) and NO metabolites in patients with ST elevation acute coronary syndrome (ACS-ST), as well as in patients with stable effort angina (SEA). Material and methods. The study involved 35 patients: 20 with ACS-ST (mean age 57,4±9,2 years) and 15 with SEA (mean age 57±7,1 years). All participants underwent standard examination and measurement of ADMA and NO metabolite (nitrites, nitrates) concentration in venous blood at admission and after 2 weeks of treatment, with the final examination at 12 months.Results. At baseline, ACS-ST patients demonstrated significant increase in ADMA and reduction in NO metabolites. After 2 weeks of treatment, no significant difference in NO metabolite levels was observed between two groups. Non-significant difference in pre- and post-treatment ADMA concentration was registered in ACS-ST patients, but this difference reached statistical significance in the subgroup of ACS-ST participants without arterial hypertension. The patients who suffered a recurrent fatal myocardial infarction within the next 12 months, demonstrated higher ADMA concentrations than all ACS individuals.Conclusion. ACS-ST patients had increased ADMA levels and reduced NO metabolite concentrations. In treated ACS-ST patients, NO metabolite levels increased.
format Article
id doaj-art-fda9ced9cbfa4ce0847c61a974242e4c
institution DOAJ
issn 1728-8800
2619-0125
language Russian
publishDate 2009-02-01
publisher «SILICEA-POLIGRAF» LLC
record_format Article
series Кардиоваскулярная терапия и профилактика
spelling doaj-art-fda9ced9cbfa4ce0847c61a974242e4c2025-08-20T02:59:54Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252009-02-01813134849Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart diseaseA. S. Galyavich0E. R. Gaynutdinov1Kazan State Medical UniversityKazan State Medical UniversityAim.То study the levels of asymmetric dimethylarginine (ADMA) and NO metabolites in patients with ST elevation acute coronary syndrome (ACS-ST), as well as in patients with stable effort angina (SEA). Material and methods. The study involved 35 patients: 20 with ACS-ST (mean age 57,4±9,2 years) and 15 with SEA (mean age 57±7,1 years). All participants underwent standard examination and measurement of ADMA and NO metabolite (nitrites, nitrates) concentration in venous blood at admission and after 2 weeks of treatment, with the final examination at 12 months.Results. At baseline, ACS-ST patients demonstrated significant increase in ADMA and reduction in NO metabolites. After 2 weeks of treatment, no significant difference in NO metabolite levels was observed between two groups. Non-significant difference in pre- and post-treatment ADMA concentration was registered in ACS-ST patients, but this difference reached statistical significance in the subgroup of ACS-ST participants without arterial hypertension. The patients who suffered a recurrent fatal myocardial infarction within the next 12 months, demonstrated higher ADMA concentrations than all ACS individuals.Conclusion. ACS-ST patients had increased ADMA levels and reduced NO metabolite concentrations. In treated ACS-ST patients, NO metabolite levels increased.https://cardiovascular.elpub.ru/jour/article/view/1137asymmetric dimethylargininenoatherosclerosiscoronary heart disease
spellingShingle A. S. Galyavich
E. R. Gaynutdinov
Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease
Кардиоваскулярная терапия и профилактика
asymmetric dimethylarginine
no
atherosclerosis
coronary heart disease
title Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease
title_full Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease
title_fullStr Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease
title_full_unstemmed Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease
title_short Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease
title_sort asymmetric dimethylarginine and no metabolites in patients with acute and chronic coronary heart disease
topic asymmetric dimethylarginine
no
atherosclerosis
coronary heart disease
url https://cardiovascular.elpub.ru/jour/article/view/1137
work_keys_str_mv AT asgalyavich asymmetricdimethylarginineandnometabolitesinpatientswithacuteandchroniccoronaryheartdisease
AT ergaynutdinov asymmetricdimethylarginineandnometabolitesinpatientswithacuteandchroniccoronaryheartdisease